Evidence map›Paper›PMID 30324119›Full record

ArticleReports of biochemistry & molecular biology2018

The Effect of Omega-3 Fatty Acids on Serum Apelin Levels in Cardiovascular Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.

Akramsadat Mortazavi, Ebrahim Nematipoor, Mahmoud Djalali, Seyed Ali Keshavarz, Simin Samavat, Mahnaz Zarei, Mohammad Hassan Javanbakht

Open access · greenAbstract read
In one paragraph

Article in Reports of biochemistry & molecular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies.European heart journal supplements : journal of the European Society of Cardiology · 2020
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Akramsadat MortazaviDepartment of cellular and molecular nutrition, School of nutritional sciences and dietetics, International Campus, Tehran University of Medical Sciences, Tehran, Iran.
Ebrahim NematipoorDepartment of cardiology, Tehran University of Medical Sciences, Tehran, Iran.
Mahmoud DjalaliDepartment of cellular and molecular nutrition, School of nutritional sciences and dietetics, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Ali KeshavarzDepartment of clinical nutrition, School of nutritional sciences and dietetics, Tehran University of Medical Sciences, Tehran, Iran.
Simin SamavatDepartment of cellular and molecular nutrition, School of nutritional sciences and dietetics, Tehran University of Medical Sciences, Tehran, Iran.
Mahnaz ZareiDepartment of cellular and molecular nutrition, School of nutritional sciences and dietetics, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Hassan JavanbakhtDepartment of cellular and molecular nutrition, School of nutritional sciences and dietetics, International Campus, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiovascular disease (CVD) is the leading cause of mortality worldwide. Omega-3 fatty acids have been shown to have both anti-atherogenic and anti-inflammatory effects through inducing the expression and production of adipokines. Adipokines such as apelin, have been observed to play a protective role in the incidence and progression of CVD. The aim of this study was to assess the influence of omega-3 fatty acids supplementation on the serum apelin levels in patients with cardiovascular disease.

methodsForty-six male patients with CVD participated in the study. Patients were randomly allocated into two groups receiving either omega-3 fatty acids or a placebo. Participants received 4 g of omega-3 fatty acids (EPA: 720 mg, DHA: 480 mg) or a placebo (edible paraffin) for 8 weeks. Serum apelin levels, high sensitive C-reactive protein (hs-CRP), and lipid profiles were measured. Dietary intake, anthropometric parameters, body composition, systolic and diastolic blood pressure were evaluated before and after the 8 weeks of intervention. Statistical analyses were performed using SPSS version 22.

resultsTwo participants from the placebo group withdrew from the study. Prior to the intervention, no significant differences were present between the two groups in age, body mass index, body composition, dietary intakes, lipid profiles and blood pressure. Compared to placebo, the intake of omega-3 fatty acids increased serum apelin levels (p= 0.018), decreased the levels of LDL cholesterol, and decreased serum hs-CRP concentrations (p= 0.007, p= 0.011 respectively). Additionally, the concentrations of VLDL, TG and hs-CRP (p= 0.037, p= 0.037 and p= 0.016 respectively) declined compared to baseline and final values in the omega-3 fatty acids group.

conclusionOmega-3 fatty acid supplementation increases serum apelin and HDL concentrations, while decreasing serum LDL-C and hs-CRP levels.

Indexed as

AdipokinesApelinCardiovascular diseaseOmega-3 fatty acids

Identifiers

PMID30324119
PMCPMC6175591
OpenAlexW2796744553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.